Virus activated killer immune cell (VAK) therapy (Binhui Biopharmaceutical)

N/A

Report date: 2024/05/30 17:10:40

Base Information

Drug NameVirus activated killer immune cell (VAK) therapy (Binhui Biopharmaceutical)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionCell replacementsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsAscitesPleural Effusion, Malignant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Binhui Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Binhui Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsAscitesPleural Effusion, Malignant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A